Nanogam (Human Normal Immunoglobulin)

Human Normal Immunoglobulin, the active ingredient in Nanogam, is a Immunoglobulin presented as a solution for injection for intravenous use. It treats primary and secondary immunodeficiency diseases and helps prevent infection in immunocompromised patients.

GNH USA supplies Nanogam as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Nanogam, an intravenous immunoglobulin, is used in conditions where the immune system lacks adequate antibody protection.

Primary immunodeficiency diseases: provides passive IgG antibodies to reduce the frequency and severity of infections. Secondary immunodeficiency: restores antibody levels in patients with acquired immune deficits, such as after chemotherapy. Prevention of infection in immunocompromised patients: supplies broad‑spectrum antibodies to help prevent bacterial and viral infections in those with weakened immunity.

Nanogam may cause a range of adverse reactions, from mild infusion‑related events to rare but serious complications.

Common Side Effects: - Headache - Fever or chills - Nausea - Fatigue - Mild infusion‑related reactions (e.g., erythema, itching) - Transient hypertension

Serious or Rare Side Effects: - Anaphylaxis or severe allergic reaction - Thromboembolic events (e.g., deep‑vein thrombosis) - Acute renal dysfunction or failure - Aseptic meningitis - Hemolysis - Severe thrombocytopenia or bleeding disorders

Before initiating Nanogam therapy, clinicians should evaluate patient‑specific risk factors and monitor for potential complications.

Monitor renal function: assess baseline creatinine and adjust infusion rate if needed. Assess thromboembolic risk: avoid use in patients with recent clotting events. Screen for IgA deficiency: patients with anti‑IgA antibodies may develop severe reactions. Observe for infusion reactions: start with a slow rate and watch for signs of hypersensitivity. Avoid concurrent live vaccines: immunoglobulin can interfere with vaccine efficacy. Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Nanogam can interact with other therapies, influencing efficacy or safety.

Major Interactions (Avoid): - Live vaccines: immunoglobulin may neutralize vaccine organisms, reducing effectiveness. - Concurrent immunoglobulin products: may increase risk of hyperviscosity and overload. - Anticoagulants (e.g., warfarin): high‑dose IVIG can alter INR and increase bleeding risk.

Moderate Interactions (Monitor Closely): - Corticosteroids: combined immunosuppression may raise infection susceptibility. - Rituximab or other B‑cell depleting agents: may affect the durability of passive immunity provided by IVIG.